Trends in the utilisation of psychotropic medications in Australia from 2000 to 2011

Australian and New Zealand Journal of Psychiatry

Volumn 47, Issue 1, 2013, Pages 74-87

  Stephenson, Chris P ^a   Karanges, Emily ^a   McGregor, Iain S ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Antidepressant; antipsychotic; anxiolytic; dispensing; psychotropic; sedative

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BROMAZEPAM; CHLORAL HYDRATE; CITALOPRAM; CLOBAZAM; DIAZEPAM; DULOXETINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; LORAZEPAM; METHYLPHENIDATE; MOCLOBEMIDE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PSYCHOTROPIC AGENT; SEDATIVE AGENT; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SERTRALINE; TEMAZEPAM; TRIAZOLAM; TRIMIPRAMINE; UNINDEXED DRUG; VALPROIC ACID; ZOLPIDEM; ZOPICLONE;

ARTICLE; AUSTRALIA; DRUG USE; HUMAN; PRESCRIPTION; PSYCHOPHARMACOTHERAPY;

ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; AUSTRALIA; CENTRAL NERVOUS SYSTEM STIMULANTS; DRUG UTILIZATION; HUMANS; HYPNOTICS AND SEDATIVES; LONGITUDINAL STUDIES; PSYCHOTROPIC DRUGS;

EID: 84873904512     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1177/0004867412466595     Document Type: Article

References (54)

1. Alexander GC, Gallagher SA, Mascola A, et al. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiology and Drug Safety. 2011 ; 20: 177-184
2. Bandelow B, Sher L, Bunevicius R, et al. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. International Journal of Psychiatry in Clinical Practice. 2012 ; 16: 77-84
3. Boyce P, Malhi GS. Supping with the devil? The dangers of liaisons between pharma and our profession. Australian and New Zealand Journal of Psychiatry. 2012 ; 46: 493-494
4. Britt H, Miller GC, Charles J, et al General Practice Activity in Australia 2010-11: BEACH, Bettering the Evaluation And Care of Health. Sydney: Sydney University Press ; 2011 :
5. Burke AD, Tariot PN. Atypical antipsychotics in the elderly: A review of therapeutic trends and clinical outcomes. Expert Opinion on Pharmacotherapy. 2009 ; 10: 2407-2414
6. Castle L, Aubert RE, Verbrugge RR, et al. Trends in medication treatment for ADHD. Journal of Attention Disorders. 2007 ; 10: 335-342
7. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: A multiple-treatments meta-analysis. The Lancet. 2009 ; 373: 746-758
8. Comer JS, Olfson M, Mojtabai R. National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007. Journal of the American Academy of Child and Adolescent Psychiatry. 2010 ; 49: 1001-1010
9. Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. Journal of Clinical Psychiatry. 2010 ; 71: 754-763
10. Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity. JAMA. 2010 ; 303: 47-53
11. Goldney R, Bain M. Prevalence of psychotropic use in a South Australian population. Australasian Psychiatry. 2006 ; 14: 379-383
12. Goodwin G. Evidence-based guidelines for treating bipolar disorder: Revised second edition - recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology. 2009 ; 23: 346-388
13. Raine ADHD Study: Long-term outcomes associated with stimulant medication in the treatment of ADHD in children. Perth: Department of Health ; 2010 :
14. Greil W, Häberle A, Haueis P, et al. Pharmacotherapeutic trends in 2231 psychiatric inpatients with bipolar depression from the International AMSP Project between 1994 and 2009. Journal of Affective Disorders. 2012 ; 136: 534-542
15. Hayes J, Prah P, Nazareth I, et al. Prescribing trends in bipolar disorder: Cohort study in the United Kingdom THIN Primary Care Database 1995-2009. PLoS ONE. 2011 ; 6: e28725
16. Hickie IB, Rogers NL. Novel melatonin-based therapies: Potential advances in the treatment of major depression. The Lancet. 2011 ; 378: 621-631
17. Hollingworth SA, Eadie MJ. Antiepileptic drugs in Australia: 2002-2007. Pharmacoepidemiology and Drug Safety. 2010 ; 19: 82-89
18. Hollingworth SA, Siskind DJ. Anxiolytic, hypnotic and sedative medication use in Australia. Pharmacoepidemiology and Drug Safety. 2010 ; 19: 280-288
19. Hollingworth SA, Burgess PM, Whiteford HA. Affective and anxiety disorders: Prevalence, treatment and antidepressant medication use. Australian and New Zealand Journal of Psychiatry. 2010a ; 44: 513-519
20. Hollingworth SA, Nissen LM, Stathis SS, et al. Australian national trends in stimulant dispensing: 2002-2009. Australian and New Zealand Journal of Psychiatry. 2011 ; 45: 332-336
21. Hollingworth SA, Siskind DJ, Nissen LM, et al. Patterns of antipsychotic medication use in Australia 2002-2007. Australian and New Zealand Journal of Psychiatry. 2010b ; 44: 372-377
22. Ilyas S, Moncrieff J. Trends in prescriptions and costs of drugs for mental disorders in England, 1998-2010. British Journal of Psychiatry. 2012 ; 200: 393-398
23. Jorm AF, Reavley NJ. Changes in psychological distress in Australian adults between 1995 and 2011. Australian and New Zealand Journal of Psychiatry. 2012 ; 46: 352-356
24. Karanges E, McGregor IS. Antidepressants and adolescent brain development. Future Neurology. 2011 ; 6: 783-808
25. Kirkbride JB, Errazuriz A, Croudace TJ, et al. Incidence of schizophrenia and other psychoses in England, 1950-2009: A systematic review and meta-analyses. PLoS ONE. 2012 ; 7: e31660
26. Komossa K, Rummel-Kluge C, Hunger H, et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews. 2010 ; ( 3 ):
27. Lader M, Tylee A, Donoghue J. Withdrawing benzodiazepines in primary care. CNS Drugs. 2009 ; 23: 19-34
28. Landmark CJ, Larsson PG, Rytter E, et al. Antiepileptic drugs in epilepsy and other disorders - A population-based study of prescriptions. Epilepsy Research. 2009 ; 87: 31-39
29. Mackey C. The anticonvulsants market. Nature Reviews Drug Discovery. 2010 ; 9: 265-266
30. Mackin P, Thomas SHL. Atypical antipsychotic drugs. British Medical Journal. 2011 ; 342: d1126
31. Mant A, Lansbury G, Bridges-Webb C. Trends in psychotropic drug prescribing in Australia. Medical Journal of Australia. 1987 ; 146: 208-210
32. Medco (2011) America's State of Mind Report. Medco Health Solutions, Inc. Available at: apps.who.int/medicinedocs/en/m/abstract/Js19032en/ (accessed 27 June 2012).
33. Melnikova I. Pain market. Nature Reviews Drug Discovery. 2010 ; 9: 589-590
34. Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Archives of General Psychiatry. 2010 ; 67: 26-36
35. Monheit B. Prescription drug misuse. Australian Family Physician. 2010 ; 39: 540-546
36. Moreno C, Laje G, Blanco C, et al. National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. Archives of General Psychiatry. 2007 ; 64: 1032-1039
37. Moylan S, Giorlando F, Nordfjærn T, et al. The role of alprazolam for the treatment of panic disorder in Australia. Australian and New Zealand Journal of Psychiatry. 2012 ; 46: 212-224
38. Olfson M, Marcus SC. National patterns in antidepressant medication treatment. Archives of General Psychiatry. 2009 ; 66: 848-856
39. Parker G. Is depression overdiagnosed? Yes. British Medical Journal. 2007 ; 335: 328
40. Partridge B, Lucke J, Hall W. Public attitudes towards the acceptability of using drugs to treat depression and ADHD. Australian and New Zealand Journal of Psychiatry. 2012 ; 46: 958-965
41. Scheffler RM, Hinshaw SP, Modrek S, et al. The global market for ADHD medications. Health Affairs. 2007 ; 26: 450-457
42. Schoepp DD. Where will new neuroscience therapies come from?. Nature Reviews Drug Discovery. 2011 ; 10: 715-716
43. Schubiner H. Substance abuse in patients with attention-deficit hyperactivity disorder: Therapeutic implications. CNS Drugs. 2005 ; 19: 643-655
44. Setlik J, Bond GR, Ho M. Adolescent prescription ADHD medication abuse is rising along with prescriptions for these medications. Pediatrics. 2009 ; 124: 875-880
45. Smith GP. For richer, for poorer, in sickness and in health: The entanglement of science and marketing. Australian and New Zealand Journal of Psychiatry. 2012 ; 46: 498-500
46. Sterne JAC, Smith GD, Cox D. Sifting the evidence - What's wrong with significance tests? Another comment on the role of statistical methods. British Medical Journal. 2001 ; 322: 226-231
47. Terzano MG, Rossi M, Palomba V, et al. New drugs for insomnia: Comparative tolerability of zopiclone, zolpidem and zaleplon. Drug Safety. 2003 ; 26: 261-282
48. Therapeutic Goods Administration (2008) Medicine regulator places boxed warning on Stilnox. Available at: www.tga.gov.au/newsroom/media-2008-stilnox- 080221.htm (accessed 27 June 2012).
49. Tsiropoulos I, Gichangi A, Andersen M, et al. Trends in utilization of antiepileptic drugs in Denmark. Acta Neurologica Scandinavica. 2006 ; 113: 405-411
50. Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. New England Journal of Medicine. 2008 ; 358: 252-260
51. Vitiello B, Correll C, van Zwieten-Boot B, et al. Antipsychotics in children and adolescents: Increasing use, evidence for efficacy and safety concerns. European Neuropsychopharmacology. 2009 ; 19: 629-635
52. Westenberg H, Sandner C. Tolerability and safety of fluvoxamine and other antidepressants. International Journal of Clinical Practice. 2006 ; 60: 482-491
53. Guidelines for ATC Classification and DDD Assignment, 2012. Oslo: WHO Collaborating Centre for Drug Statistics Methodology ; 2011 :
54. Zuvekas SH, Vitiello B. Stimulant medication use in children: A 12-year perspective. American Journal of Psychiatry. 2012 ; 169: 160-166